Home -> Law Blog Directory -> Intellectual Property Law Blogs -> TinytechIP
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Intellectual Property Law
: TinytechIPUS Patent 7700915 - Characterization of crystalline tubular molecules
This patent from Canatu Oy proposes a new method for characterizing carbon nanotubes using electron diffraction. The method provides more reliable results by correcting for anomalous tilt angle of the electron beam. Claim 1 reads:
1. A method for determining the atomic structure of at least one tubular crystalline molecule, wherein the method comprises the following steps: obtaining an electron diffraction pattern of at least one tubular crystalline molecule; calculating at least one feature of the atomic structure and/or range of atomic structures using at least one calibration-free property of the electron diffraction pattern; and compensating for an effect of an unexpected, unknown or otherwise uncontrolled tilt angle of the tubular crystalline molecule with respect to an electron beam.
Full post as published by TinytechIP on April 21, 2010 (boomark / email).
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.
Sony
to Pay $18.5 Million For Patent Infringment
Qualcomm Settles Patent Suit for $891 Million
The Princeton Review
$2.6 million settlement reached in patent infringement case.

Developing IP Strategies for Crystalline Forms Conference
Patent Profile: NexBio Granted U.S. Patent for Flu Therapeutic
Prohibited Words in a Patent – “Prior Art”
Tired of Using a Sweaty Golf Glove If so, This Invention May be for You
Are trade secrets nothing but baby patents
Isis Pharmaceuticals Adds to Crooke RNAi Patent Estate








